BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210928
DTEND;VALUE=DATE:20211001
DTSTAMP:20260515T212900
CREATED:20210524T114659Z
LAST-MODIFIED:20210524T114953Z
UID:30324-1632787200-1633046399@www.pharmajournalist.com
SUMMARY:4th Annual Neuropsychiatric Drug Development Summit
DESCRIPTION:This last year has been a brutal reminder as to how crucial it is that we tackle the impending global mental health crisis and find a path towards successful neuropsychiatric drug development. \nWe are proud to be the industry’s definitive and unrivalled forum focused on encapsulating the recent clinical advances across this extremely arduous field. This timely meeting provides a much-needed platform for industry and academic thought leaders to: \n\nInvestigate new treatment paradigms to support schizophrenia patients with Sunovion\, Merck\, Cerevel and BioXcel\nStrive for useful biomarkers in clinical practice and explore novel electrophysiological biomarkers of synaptic plasticity in humans with Lundbeck\, Daniel Javitt and Takeda\nHear patient-centric approaches towards developing efficacious and engaging digital therapeutics with Thomas Insel\, MindMed\nDecipher the recent hype in psychedelics by evaluating new data emerging on hallucinogens with Psilera\, MAPS\, Eleusis\, ATAI and Perception Neuroscience\nDiscover the major advances in understanding neuroinflammation across CNS indications and how can we use this to help us further understand psychiatric conditions with Johnson & Johnson and Inmune Bio\n\nDon’t miss out and join over 80 of your peers at this timely event to take a step closer towards your ambitious goal of drastically improving the lives of individuals living with neuropsychiatric disorders. \nTo know more about 4th Annual Neuropsychiatric Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/4th-annual-neuropsychiatric-drug-development-summit/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210929
DTEND;VALUE=DATE:20211002
DTSTAMP:20260515T212900
CREATED:20210521T123937Z
LAST-MODIFIED:20210521T124307Z
UID:30236-1632873600-1633132799@www.pharmajournalist.com
SUMMARY:12th Annual World Bispecific Summit
DESCRIPTION:The 12th Annual World Bispecific Summit will deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover unique discovery\, translational\, and manufacturing challenges faced in the bispecific field. Whatever your role and interest\, you will leave the meeting with concrete methods to employ into your strategy and pipeline to convert the promise of bispecific therapeutics into a reality for patients. \n \nDiscover who the 45+ expert speakers are\, and the topics they will examine\, including how: \n\nOSE Immunotherapeutics is pioneering their unique platform BiCKI a bispecific platform optimized for the development and manufacturing of bispecific cytokine fusion proteins\nGT Biopharma and Light Chain Bioscience are showcasing the next generation of innate cell engagers for the treatment of solid tumors\nMerus\, Pfizer\, and Innate Pharma are expanding the boundaries of biotherapeutics with tri-specific and multi-specific antibodies\nGenentech\, Pfizer\, and City of Hope are discussing approaches to reduce on-target off-tumor toxicities including dosing strategies in liquid and solid tumor indications\nXencor\, Harbour Biomed\, and Harpoon Therapeutics will discuss their unique platforms and CMC strategies for scale-up and production\nIGM Biosciences and MacroGenics will evaluate biomarker strategies for bispecific candidates during clinical development\n\nTo know more about 12th Annual World Bispecific Summit please click here.
URL:https://www.pharmajournalist.com/event/12th-annual-world-bispecific-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210929
DTEND;VALUE=DATE:20211001
DTSTAMP:20260515T212900
CREATED:20210721T205309Z
LAST-MODIFIED:20210721T205309Z
UID:31026-1632873600-1633046399@www.pharmajournalist.com
SUMMARY:11th World Clinical Biomarkers & CDx Summit
DESCRIPTION:Accelerating R&D to Commercialization by Leveraging Predictive Biomarkers & Clinical Diagnostics Evidence for Best Patient Outcomes in Target Populations \nThe 11th World Clinical Biomarkers & CDx Summit returns in 2021 as the only end-to-end industry-led meeting diving deep into the science of transitioning biomarkers to the clinic\, their clinical validation and later commercialization with a CDx. \nWith over half of drugs approved by the FDA now supported by a biomarker and as new CDx collaborations are announced on an almost weekly basis\, demand for diagnostic tools enabling earlier\, more precise\, therapeutic interventions is at an all time high. Join with 650+ key stakeholders across biomarker\, translational\, clinical\, regulatory and commercial functions to tackle end-to-end challenges and deliver game-changing drug-Dx products to market. \nAcross 2 days of comprehensive content\, 65+ global expert speakers will share fresh data paired with inspiring stories from innovative partnership collaborations to help you overcome your most pressing challenges and accelerate curative medicine for heterogeneous patient populations. \nWith 3-tracks addressing the entire lifecycle of biomarker-driven drug development\, explore biomarkers and Dx movement within bioanalytical analysis\, AI/ML application\, data sharing and the regulatory and payer landscape. Covering immune-oncology\, neurodegenerative\, metabolic\, autoimmune and rare indications\, gain a diverse picture of today’s expanding personalized medicine ecosystem. \nThis is your unmissable event\, bringing you the tools\, insights and techniques to design a clinically robust biomarker and commercially competitive CDx! \nTo know more visit: https://world-cdx.com/
URL:https://www.pharmajournalist.com/event/11th-world-clinical-biomarkers-cdx-summit/
LOCATION:Digital
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR